BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


SEARCH JOBS










 Company News
Nabriva Appoints Elyse Seltzer MD As Chief Medical Officer 5/21/2015 9:15:34 AM
Nabriva Presents Data On Extended Spectrum Pleuromutilin Antibiotics At The 25th European Congress Of Clinical Microbiology And Infectious Diseases, Copenhagen 4/24/2015 1:25:06 PM
Nabriva Raises $120 Million, Headed to Phase III for New Antibiotic 4/7/2015 5:50:04 AM
Nabriva Therapeutics Strengthens Board And Management Team 1/29/2015 10:51:08 AM
Nabriva Therapeutics Announces Qualified Infectious Disease Product And Fast Track Status Granted By The US FDA For Lefamulin 10/8/2014 9:16:26 AM
Nabriva Therapeutics Presented Data On Lead Pleuromutilin Antibiotic Lefamulin (BC-3781) At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy In Washington DC 9/8/2014 9:23:23 AM
Nabriva Therapeutics Appoints Dr. Colin Broom As CEO 9/3/2014 6:37:02 AM
Nabriva Therapeutics Presents Extended Spectrum Pleuromutilin Antibiotics At The 24th European Congress Of Clinical Microbiology And Infectious Diseases, Barcelona 5/12/2014 12:12:26 PM
Forest Laboratories, Inc. (FRX) Coughs Up $25 Million for Nabriva Therapeutics's Phase II Antibacterial, Right to Take Over Company 6/1/2012 6:42:35 AM
Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process 9/27/2011 10:42:28 AM
123